Cadila Healthcare, a Rs.8,500 crore Ahmedabad based pharma major, has registered strong growth in bottom line during the second quarter ended September 2015. Its consolidated net profit moved up 40.6 per cent to Rs.390.91 crore from Rs.278.09 crore in the corresponding period of last year and EBIDTA went up by 48.1 per cent to Rs.546 crore from Rs.436 crore. Its net sales increased by 15 per cent to Rs.2,374 crore from Rs.2,064 crore. With improvement in profits, EPS moved up to Rs.19.09 from Rs.13.58 in the last period.

Its US business registered growth of 25 per cent to Rs.1,004 crore and it received approval for one new product from the US FDA. It launched two new products in US. The company launched 13 new products in the domestic market, including extensions, of which 4 products were the first to be launched in India. In Mexico, it launched 2 new products, taking cumulative launches to over 15 and received the regulatory approval for 6 more dossiers, taking the cumulative number of approvals to over 30.

Cadila scrip opened at Rs.452.10 on BSE today as against its previous day's close of Rs.431.65.

For the first half ended September 2015, Cadila's consolidated net sales increased by 15.7 per cent to Rs.4,752 crore from Rs.4,084 crore in the similar period of last year. Its net profit has taken a jump of 43.6 per cent and touched to Rs.744 crore from Rs.518 crore. EPS worked out to Rs.36.35 as against Rs.25.31 in the same period of last year.  

It's standalone net sales for the second quarter increased by 56.6 per cent to Rs.1,751 crore from Rs.1,118 crore and it posted net profit of Rs.614 crore as compared to Rs.366 crore, a growth of 68 per cent.